EQRx to Participate in Cowen’s 42nd Annual Health Care Conference
March 02, 2022 08:00 ET
|
Eqrx, Inc.
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at...
Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer
January 18, 2022 19:00 ET
|
Eqrx, Inc.
Pivotal Phase 3 GEMSTONE-302 trial met key secondary endpoint of prolongation of overall survival with sugemalimab plus chemotherapy versus placebo plus chemotherapyOverall survival benefit...
EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III and Stage IV Non-Small Cell Lung Cancer
January 18, 2022 08:00 ET
|
Eqrx, Inc.
Results from the pivotal Phase 3 GEMSTONE-301 study demonstrated that sugemalimab, an anti-PD-L1 antibody, improves progression-free survival (PFS) in patients with Stage III non-small cell lung...
EQRx Enters Memorandum of Understanding with CVS Health to Create Cost Savings and Improve Patient Access to Innovative Medicines
January 10, 2022 07:30 ET
|
Eqrx, Inc.
The two companies will explore opportunities for a long-term, strategic partnership spanning the CVS Health enterpriseIncludes CVS Caremark, the leading pharmacy benefit manager in the U.S., covering...
EQRx and Geisinger Sign Memorandum of Understanding to Provide Access to Innovative Cancer Medicines at Radically Lower Costs
January 07, 2022 08:00 ET
|
Eqrx, Inc.
Provides roadmap to commercial agreement between EQRx and Geisinger, a U.S.-based integrated delivery networkPotential to provide access to affordable treatments in areas of high-cost burden for more...
EQRx to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022 08:00 ET
|
Eqrx, Inc.
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at...
EQRx Debuts as Publicly Traded Company to Develop and Deliver Innovative Medicines at Radically Lower Prices
December 17, 2021 12:45 ET
|
Eqrx, Inc.
Business combination with CM Life Sciences III results in approximately $1.3 billion in cash proceedsCombined company to trade on Nasdaq Global Market under ticker “EQRX” NEW YORK and CAMBRIDGE,...